Regulus Therapeutics INC

Regulus Therapeutics Inc. has been acquired by Novartis AG's indirect wholly-owned subsidiary, Redwood Merger Sub Inc., for $7.00 per share in cash plus a contingent value right, following a successful tender offer.

Regulus Therapeutics announces acquisition by Novartis for $7.00 per share in cash, with a potential additional $7.00 per share via a contingent value right, alongside positive Phase 1b data for farabursen in ADPKD.

Novartis AG will acquire Regulus Therapeutics for $7.00 per share in cash, plus a contingent value right (CVR) of up to $7.00 per share, potentially valuing the company at approximately $1.7 billion.

Regulus Therapeutics reports positive topline results from the fourth cohort of its Phase 1b study of farabursen (RGLS8429) for autosomal dominant polycystic kidney disease (ADPKD), showing a halting of kidney volume growth.

Regulus Therapeutics reported positive interim results from a Phase 1b trial of farabursen for ADPKD and alignment with the FDA on a Phase 3 trial design, along with its year-end 2024 financial results.

Regulus Therapeutics extends its lease agreement for its San Diego facility, ensuring continued operations at its current location until April 2028.

Regulus Therapeutics reports Q1 2025 results, highlighting ongoing losses and liquidity concerns despite a pending acquisition by Novartis.

Regulus Therapeutics Inc. has released its financial results for the third quarter of 2024, alongside updates on its clinical programs, particularly RGLS8429 for ADPKD.

Regulus Therapeutics reported a net loss of $11.0 million for the second quarter of 2024, while highlighting progress in its RGLS8429 clinical trial for ADPKD.

Regulus Therapeutics reported a net loss of $8.5 million for the first quarter of 2024, while highlighting progress in its RGLS8429 clinical trial for ADPKD.

Regulus Therapeutics files an amendment to its annual report on Form 10-K to include information required in Part III, which was not initially included due to the delay in filing the definitive proxy statement.

Regulus Therapeutics advances farabursen clinical development for ADPKD while navigating financial uncertainties.

Regulus Therapeutics Inc. has filed its annual 10-K report, disclosing executive salary increases and providing an overview of its financial status and clinical development programs.

Regulus Therapeutics Inc. director William H. Rastetter has disposed of his common stock and derivative securities as the company completed its merger, becoming a wholly-owned subsidiary of Novartis AG.

Pascale Witz, a Director of Regulus Therapeutics Inc., has reported the disposition of all her beneficial ownership in the company's securities, effective June 25, 2025, due to the completion of the merger with Novartis AG.

Regulus Therapeutics Inc. has been acquired by Redwood Merger Sub Inc., a Novartis AG subsidiary, resulting in the disposition of all common stock, options, and warrants held by Director Stelios Papadopoulos in exchange for cash and contingent value rights.

A recent SEC Form 4 filing reveals that Hugh Rosen, a Director at Regulus Therapeutics Inc., has disposed of all his common stock, restricted stock units, and stock options as a result of the company's acquisition by Novartis AG.

Preston Klassen, President and Head of R&D at Regulus Therapeutics Inc., has disposed of all his common stock, performance stock units, and stock options following the completion of the company's acquisition by Novartis AG.

A senior executive at Regulus Therapeutics Inc. has filed a Form 4 detailing the conversion of his equity holdings into cash and contingent value rights as a result of the company's acquisition by Novartis AG.

Regulus Therapeutics amends its proxy statement to include details about its engagement with Alliance Advisors LLC for proxy solicitation.

Regulus Therapeutics is holding its annual meeting on May 16, 2024, to vote on director elections, executive compensation, auditor ratification, and an amendment to the equity incentive plan.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen collectively reported a 0.3% beneficial ownership stake in Regulus Therapeutics Inc., primarily through warrants.

Deep Track Capital and its affiliates have fully divested their beneficial ownership in Regulus Therapeutics Inc., reporting 0% stake.

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have filed an amended Schedule 13G, disclosing a 3.9% passive beneficial ownership in Regulus Therapeutics Inc.

Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a passive 5.9% beneficial ownership stake in Regulus Therapeutics Inc., including shares issuable from warrants.